Leerink raised the firm’s price target on Idexx Laboratories (IDXX) to $785 from $745 and keeps an Outperform rating on the shares. The firm notes the company’s Q3 print and guide increase were impressive, serving as another reminder of its best-in-class competitive positioning and amenable end markets. Idexx posted strong organic growth in the U.S. and International CAG recurring Dx businesses, underscoring the size of the current diagnostic market opportunity and the company’s ability to execute against it. Idexx clearly continues to execute well, using the growth levers that it has at its disposal to drive results, says Leerink.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $775 from $700 at Stifel
- Early notable gainers among liquid option names on November 3rd
- Idexx Laboratories reports Q3 EPS $3.40, consensus $3.14
- Idexx Laboratories raises FY25 EPS view to $12.81-$13.01 from $12.40-$12.76
- These Are the Stocks Reporting Earnings Today – November 3, 2025